Cargando…
Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus
The efficacy and safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, as monotherapy have been widely confirmed in a large body of clinical studies of up to 2 years’ duration in various populations with type 2 diabetes mellitus. This paper reviews the data supporting the use of vildagliptin...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3363148/ https://www.ncbi.nlm.nih.gov/pubmed/22661900 http://dx.doi.org/10.2147/VHRM.S31758 |